Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monte Rosa TherapeuticsGLUE +6.51%32 Quick Ratio is 9.54 as of Mar. 2026, which is 18% above its 10-year median of 8.09. GuruFocus rates GLUE with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Monte Rosa Therapeutics ranks better than 77.32% on this metric.
Monte Rosa Therapeutics has a quick ratio of 9.54. It generally indicates good short-term financial strength.
The historical rank and industry rank for Monte Rosa Therapeutics's Quick Ratio or its related term are showing as below:
GLUE'
s Quick Ratio Range Over the Past 10 Years
Min: 1.49 Med: 8.09 Max: 33.2
Current: 9.54
During the past 7 years, Monte Rosa Therapeutics's highest Quick Ratio was 33.20. The lowest was 1.49. And the median was 8.09.
GLUE's Quick Ratio is ranked better than 77.32% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs GLUE: 9.54
Monte Rosa Therapeutics (NAS:GLUE) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Monte Rosa Therapeutics Quick Ratio Related Terms
Monte Rosa Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Monte Rosa Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monte Rosa Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Monte Rosa Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Monte Rosa Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics (GLUE) has a Quick Ratio of 9.54 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Monte Rosa Therapeutics and its competitors. This is 18% above median its historical median of 8.09. Over the past decade, Monte Rosa Therapeutics' Quick Ratio has ranged from 1.49 to 33.20. According to the industry distribution chart, Monte Rosa Therapeutics ranks #320 out of 1411 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Monte Rosa Therapeutics' Quick Ratio too high?
Monte Rosa Therapeutics' current Quick Ratio of 9.54 is 18% above median its 10-year median of 8.09. Over the past 10 years, this metric has ranged from a low of 1.49 to a high of 33.20. The Biotechnology industry median Quick Ratio is 3.59. Monte Rosa Therapeutics' value of 9.54 is 165.7% above this industry median. Based on the distribution chart, Monte Rosa Therapeutics ranks #320 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monte Rosa Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Quick Ratio compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #320 out of 1411 companies for Quick Ratio. This places Monte Rosa Therapeutics in the top 23% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Monte Rosa Therapeutics' value of 9.54 is 165.7% above this benchmark. Historically, Monte Rosa Therapeutics' own Quick Ratio has ranged from 1.49 to 33.20 over the past decade. While the company's 10-year median is 8.09 vs. the industry median of 3.59, Monte Rosa Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monte Rosa Therapeutics's current Quick Ratio of 9.54 is 165.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Monte Rosa Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monte Rosa Therapeutics's current Quick Ratio is 9.54, which is 18% above median its own 10-year median of 8.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Quick Ratio of 9.54. The current Quick Ratio is 9.54, which is 18% above median its 10-year median of 8.09 and 165.7% above the Biotechnology industry median of 3.59. Monte Rosa Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Quick Ratio is 9.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
32GF Score
Get the complete analysis for GLUE
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLUE has been successfully added to your 
